NCT00506519View on ClinicalTrials.gov

Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Disseminated Intravascular Coagulation
Interventions
DRUG

Antithrombin alfa (INN name)

DRUG

Control (Standard treatment)

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY